Eloralintide: The New Weight Loss Medication That Works Differently From GLP-1s

By GLPeak Team · 2026-08-18

Move over GLP-1s. Discover how eloralintide uses a unique amylin-based approach to redefine weight loss and appetite control in a way Ozempic and Zepbound don't.

If you follow obesity medicine news, you may have started hearing the name eloralintide. It is not a GLP-1 medication, and it doesn't work the way semaglutide or tirzepatide does. Depending on how its ongoing trials play out, it could meaningfully expand what treatment looks like for people managing obesity.

A Different Hormone, A Different Approach

GLP-1 medications mimic gut hormones that slow digestion, stimulate insulin release, and reduce appetite. They've been transformative for millions of people, and they all work through the same general system.

Eloralintide targets a different hormone called amylin. Amylin is released by the pancreas after eating. Its job is to tell the brain that a meal is winding down, slowing digestion and helping keep blood sugar stable afterward. In people with obesity, amylin signaling is often impaired, which may reduce the feeling of fullness. Eloralintide mimics amylin to reinforce those signals, and it's given as a once-weekly injection.

How It Compares to Cagrilintide

Novo Nordisk is developing an amylin-based medication called cagrilintide, part of their CagriSema combination. Both target amylin, but not in the same way.

Amylin receptors are built from calcitonin receptors combined with accessory proteins, which means the two receptor types are closely related. Cagrilintide activates both, which is why it's formally classified as a dual amylin and calcitonin receptor agonist. Eloralintide was engineered to activate amylin receptors with minimal calcitonin receptor activity.

Whether that difference produces better outcomes in patients is an open question. The two medications have never been compared head to head.

In the Phase 3 REDEFINE 1 trial, cagrilintide alone produced 11.8% weight loss at 68 weeks. Eloralintide's Phase 2 reported roughly 20% at its highest doses over 48 weeks. Those numbers come from different trial populations, dose ranges, durations, and analysis methods, however, so the gap between them should not be read as a straightforward efficacy difference.

What the Human Trials Show

The main evidence comes from a Phase 2 trial published in The Lancet in November 2025. It enrolled 263 adults across 46 US research centers, all with obesity or overweight plus at least one weight-related health condition, and none with type 2 diabetes. Participants received once-weekly injections of eloralintide at one of several doses, or placebo, for 48 weeks.

Every dose group beat placebo. Average weight loss was dose-dependent, ranging from about 9% at the 1mg dose to about 20% at 9mg, compared with 0.4% on placebo.

Side effects deserve an honest look. Nausea and fatigue were the most common, and both were dose-dependent. At the two lowest doses, rates were close to placebo. At higher, more effective doses they were considerably more common, with nausea reported by a third of participants at 9mg and fatigue by 43%. How the dose was escalated mattered as well: participants who worked up gradually from 3mg reported nausea at 25%, compared with 64% among those started directly at 6mg.

Where Things Stand Now

Phase 3 is underway across several patient populations. ENLIGHTEN-1, the primary obesity trial, began enrolling in January 2026 with a target of roughly 1,980 participants and a primary completion estimate in 2028. Additional Phase 3 trials are studying eloralintide in people with type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis.

There is no announced FDA submission date. Given where the trials sit, approval is realistically several years away.

What This Could Mean for People on GLP-1 Medications

The most relevant question for anyone already on a GLP-1 is whether eloralintide might eventually be added rather than swapped in.

GLP-1 medications and amylin-based medications act on different parts of the appetite regulation system. For someone who has responded well to a GLP-1 but hit a plateau, adding a medication that targets a separate pathway could theoretically produce additional benefit rather than starting over with a different mechanism.

A Phase 3 trial called ENLIGHTEN-6 is testing exactly this, studying once-weekly eloralintide in adults with persistent obesity or overweight who are already being treated with a weekly incretin medication, with and without type 2 diabetes. Results from that trial will be worth watching closely.

References: 1. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025. doi:10.1016/S0140-6736(25)02155-5 2. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun. 2025. https://www.nature.com/articles/s41467-025-58680-y 3. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081. ClinicalTrials.gov identifier NCT05567796. 4. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1). ClinicalTrials.gov identifier NCT07321886. 5. Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Persistent Obesity or Overweight Treated with a Weekly Incretin with and without Type 2 Diabetes (ENLIGHTEN-6). ClinicalTrials.gov identifier NCT07392190.

This blog is for informational purposes only and does not constitute medical advice. Eloralintide is an investigational medication and is not FDA approved. Always consult your healthcare provider before making any changes to your treatment.